High-dose melphalan allows durable engraftment of allogeneic bone marrow. uri icon

Overview

abstract

  • Conditioning regimens for allogeneic bone marrow transplantation are designed to eradicate malignant cells and to provide sufficient immunosuppression for engraftment of donor marrow. Total body irradiation and high-dose cyclophosphamide are the most established immunosuppressive agents used for this purpose. It is uncertain whether other alkylating agent-based conditioning regimens are sufficiently immunosuppressive to allow engraftment of allogeneic marrow. We report four patients who had prompt engraftment after conditioning with melphalan-based chemotherapy regimens (BEAM or busulfan/melphalan). Two patients survived without disease for a prolonged period, indicating that these melphalan regimens are sufficiently immunosuppressive to allow sustained engraftment and donor hematopoiesis.

publication date

  • February 1, 1995

Research

keywords

  • Bone Marrow Transplantation
  • Graft Rejection
  • Hodgkin Disease
  • Melphalan
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Identity

Scopus Document Identifier

  • 0028959923

PubMed ID

  • 7773226

Additional Document Info

volume

  • 15

issue

  • 2